Posted by Bob on March 3, 2002, at 21:26:34
In reply to Re: New Glaxo / Merck antidepressant, posted by SLS on March 3, 2002, at 19:33:15
> Here's a new one (sort of):
>
> http://pharmalicensing.com/news/adisp/982274821_3a8c5305199e4
>
> Excerpts:
>
> "GlaxoSmithKline plc and Merck KGaA have signed a worldwide
> development and commercialisation agreement for an antidepressant
> with a novel mechanism of action."
>
> "The compound, currently known as EMD 68843 or SB 659746-A, is in
> Phase II clinical development."
>
> "It combines the properties of a selective serotonin- reuptake
> inhibitor with those of a 5-HT1A partial agonist."
>
>
> Does anyone know how long it takes for a drug in phase-II trials to be approved?
>
> - Scott--------------------------------------------------
Scott:
Forgive me for being obtuse here, but could you explain to me why the drug you described is so unique? What are the advantages of a compound which is an SSRI, yet has a 5HT1A partial agonist property?
Bob
poster:Bob
thread:95939
URL: http://www.dr-bob.org/babble/20020301/msgs/96241.html